Indivior Plc

91.00 (5.72%)
Share Name Share Symbol Market Type Share ISIN Share Description
Indivior Plc LSE:INDV London Ordinary Share GB00BN4HT335 ORD USD0.50
  Price Change % Change Share Price Shares Traded Last Trade
  91.00 5.72% 1,681.00 1,036,981 16:35:25
Bid Price Offer Price High Price Low Price Open Price
1,669.00 1,671.00 1,671.00 1,600.00 1,600.00
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceutical Preparations 901.00 -53.00 -38.80 - 2,294.25
Last Trade Time Trade Type Trade Size Trade Price Currency
18:45:05 O 2,121 1,660.85 GBX

Indivior (INDV) Latest News

Indivior (INDV) Discussions and Chat

Indivior Forums and Chat

Date Time Title Posts
09/3/202010:34RB. de-merger 548
11/7/201908:29Johnson & Johnson court case oklahoma6
03/5/201910:16Judgement against insys2
31/7/201813:45Indivior (INDV) IP Battle Status -

Add a New Thread

Indivior (INDV) Most Recent Trades

Trade Time Trade Price Trade Size Trade Value Trade Type
2023-06-06 17:45:051,660.852,12135,226.63O
2023-06-06 16:53:591,681.0011,029185,397.49O
2023-06-06 16:53:591,681.002293,849.49O
2023-06-06 16:53:281,681.005128,606.72O
2023-06-06 16:52:121,681.146,640111,627.36O

Indivior (INDV) Top Chat Posts

Top Posts
Posted at 05/6/2023 14:15 by steeplejack
The marketmakers will be having extra fun arbitraging with the US quote in due course.Charles Schwab in the US don't charge commission and (of course theres no transaction stamp duty to pay)so you can factor in a price differential between the US and UK quotes of around 0.6% ie about 10p even before the MMs get up to their tricks.I always feel appreciative when i can nip into the US market and pay effectively nothing to deal.The very idea must be deeply shocking to the UK government.
Posted at 05/6/2023 09:56 by steeplejack
ShearClass over on LSE has posted an interesting analysis.Alkermes (ALKS) is a NASDAQ listed pharma that market another opoid dependence drug (vivitrol). Their Q1 revenues were $287m with $96.7m of this coming from vivitrol, up from $84.7m in the prior year. They're trading at an enterprise value of $4.5b, so EV/Sales ratio is ~3.9. INDV is forecasting 2023 sales of $1.01b and has a current EV of ~$2.4b, so is on an EV/Sales of just 2.3x Gives INDV has significantly faster sales growth, higher gross margins & has now removed the legal overhang I think there is significant upside potential over the coming weeks post next Monday's NASDAQ listing. Aligning with the Alkermes EV/s would put the share price at around £26...
Posted at 27/5/2023 12:34 by dealy
I would say the death of the retail stock picker / investor is pretty much universal. Hardly anyone i know across many countries would even consider buying a single share (other than the uber caps like Apple).For most small and mid caps the only way to get a reasonable valuation is to sell the company, but that is an activity which is also in the doldrums. Dividends and buy backs can help but that requires profits and no nasties on the horizon
Posted at 24/5/2023 09:59 by maywillow
Indivior to Commence Trading on Nasdaq Global Select Market in June
05/24/2023 | 04:17am BST

(MT Newswires) -- Indivior (INDV.L) said Tuesday it expects to start the trading of its ordinary shares on the Nasdaq Global Select Market on June 12 under the ticker INDV.

The pharmaceutical company will retain its premium listing on the London stock exchange and terminate its American depository receipt program, with the shares to be exchanged for Indivior shares on a 1:1 basis.

The US listing remains subject to the approval of the Securities and Exchange Commission.

Shares in Indivior were down more than 2% on Tuesday's close.

Price (GBP): £1470.00, Change: £-31.00, Percent Change: -2.07%

Posted at 19/5/2023 16:10 by gregmorg
I see the Indivior share price movement today and have presumed that the PDUFA for OPNT003 with a designated date of 22 May 2023 is somewhat behind it
Posted at 08/2/2023 07:24 by adrian j boris
(MT Newswires) -- Indivior (INDV.L) received the Committee on Foreign Investment in the US approval to acquire Nasdaq-listed Opiant Pharmaceuticals, according to a Tuesday release.

The clearance comes after the committee found that the proposed deal poses no unresolved national security concerns. The UK Competition and Markets Authority also decided to take no further action.

In November 2022, Indivior agreed to make an upfront cash payment of $20 per share, or a total of $145 million, plus up to $8 per share in contingent value rights, subject to the achievement of certain net revenue milestones in the seven years after the launch and approval of OPNT003, or nasal nalmefene.

The US pharmaceutical company's board unanimously recommended that shareholders vote in favor of the merger at a meeting on March 1.

Indivior's London shares fell marginally at the close of trading on Tuesday.

Posted at 07/12/2022 07:52 by grupo guitarlumber
07 December 2022

Indivior Capital Markets Day Highlights Strategy for Shareholder Value Creation

and Attractive Medium-Term Profitable Growth Outlook

- Peak Annual Net Revenue Potential for SUBLOCADE (R) Increased to >$1.5 Billion

- Attractive and Scalable Business Outlined - Expects Strong Net Revenue Growth and Operating Margin Expansion Over the Medium-term

- Disciplined Approach to Capital Allocation Maintained

- NASDAQ Listing Targeted for Spring 2023

This Release Contains Inside Information.

Slough, UK, and Richmond, VA, December 7, 2022 - Indivior PLC (LON: INDV) will hold a Capital Markets Day today in New York City. The event will be hosted by Mark Crossley, Chief Executive Officer, along with members of the Indivior executive leadership team and will detail the Company's strategic growth plans and roadmap for delivering long-term shareholder value.

"We have made tremendous progress executing on our strategic priorities," said Mark Crossley. "We are the pioneer and global leader in addiction treatment and science and are well-positioned to transform the lives of the increasing number of patients affected by the opioid crisis, one of the most urgent public health emergencies of our time. Today, my team and I are excited to provide a deep review of our business and to highlight the compelling opportunities we have to innovate in the treatment of addiction and serious mental illness while delivering profitable growth and significant value creation for shareholders."

-- Increases SUBLOCADE peak annual net revenue (NR) expectations to >$1.5 billion

Indivior expects SUBLOCADE(R) (buprenorphine extended-release) injection to achieve a NR run rate of $1 billion by the end of 2025, driven by its focus on further developing the Organized Health Systems (OHS) channel and pursuing the large opportunity in the U.S. Justice System. Longer term, based on the expected positive market dynamics for buprenorphine medication-assisted treatment (BMAT) and on continued execution against its OHS strategy, Indivior now expects to deliver SUBLOCADE peak potential NR of >$1.5 billion.

-- Expects to achieve attractive double-digit % NR compounded annual growth rate (CAGR) over the medium-term

Indivior expects to achieve a double-digit percentage NR CAGR over the medium-term, driven primarily by SUBLOCADE in the United States and growing NR contribution from PERSERIS(R) (risperidone for extended-release injection). Within this outlook, which is based on its current business portfolio, Indivior also expects a return to NR growth in the Rest of the World driven by new products SUBLOCADE (SUBUTEX (R) PR) and SUBOXONE (R) (buprenorphine/naloxone) Film. Additionally, the Company assumes the U.S. market share of SUBOXONE Film, which it does not promote, will trend towards historical analogs for genericized medicines.

-- Operating margin expansion opportunity from scalable business model

Indivior expects to achieve significant operating margin expansion over the medium-term driven by an improving gross margin and focused management of operating expenses. Following the significant structural growth investments behind SUBLOCADE and PERSERIS in the past two years, selling, general and administrative (SG&A) expenses are expected to grow at a more moderate pace and to decline as a percentage of NR. This impact is expected to be partly offset by an increase in R&D expenses as a percentage of NR towards industry benchmarks as the Company seeks to build a strong and balanced pipeline focused on addiction treatments.

-- Disciplined capital allocation approach focused on driving growth and potential returns of excess cash

In the past two years, Indivior's healthy balance sheet and improved cash flow have supported a balanced approach towards capital allocation, focused on investment in key growth priorities, diversifying the business, delivering shareholder returns and meeting other stakeholder obligations. The recently announced definitive agreement to acquire Opiant Pharmaceuticals, Inc. (NASDAQ: OPNT) is indicative of Indivior's commitment to diversify its product portfolio and to expand its global leadership in addiction treatment and science.

-- Listing on NASDAQ targeted for the Spring of 2023

At its Extraordinary General Meeting (EGM) in September of this year, Indivior received strong support from its shareholders for an additional share listing in the United States. Having carefully evaluated the available options, Indivior has chosen NASDAQ as its U.S. trading venue. The additional listing is expected to elevate Indivior's profile in the Company's largest market and to attract a broader group of biopharma-focused investors and analysts.

The Group reiterates its FY 2022 guidance published on October 27, 2022.

Event Details

Today's event will begin at 8:30am EST and conclude at 12:30pm EST. Due to limited availability, in-person participation is limited to institutional investors and analysts. For those wishing to attend in person, please RSVP to and further location details will be provided.

Further details can be found at

To access the live webcast, please click INDV CMD 2022 .

A webcast replay will be available after the event has concluded.

The person responsible for making this announcement is Kathryn Hudson, Company Secretary.

Posted at 08/9/2022 11:21 by steeplejack
So we're going to have a 1:5 consolidation which will give a share price of well over £14 at current share prices.Whilst heavyweight prices in the US are popular (taken to reflect a successful past) the attitude in the UK is more parochial.UK punters have a penchant for penny stocks,taking some strange comfort in the fact that they hold a sizeable number of me,its true!So consolidations are not always that well received in the UK albeit that brokers are becoming more adept at making the updating of nominee accounts quicker and more seamless.
Posted at 12/3/2022 17:05 by typo56
The news is quite possibly a continuation of this from 23 Feb..

"Indivior, the FTSE 250-listed opiod addiction treatment company, is rumoured to be the mystery bidder circling Opiant Pharmaceuticals, the US-listed developer of medicines for drug addiction.

People following the situation have heard rumours Indivior has been talking to Opiant since December last year year about a possible offer for the company."

Good or bad for the INDV share price? You decide!

Posted at 15/1/2021 17:52 by grupo guitarlumber
Indivior is the biggest FTSE 250 gainer today. Would I buy it now?

Manika Premsingh | Friday, 15th January, 2021

Business development to success and FTSE 100 250 350 growth concept.

The FTSE 250 opioid addiction treatment provider Indivior (LSE: INDV) is the biggest index gainer today as I write. Its share price is up 9%, continuing its recovery after a sharp fall in late November.

Why the share price rose

INDV’s better-than-expected financial results are the clear reason for the uptick in share price. It now expects revenue to be at least $25m higher than it had expected earlier for the full year. It also expects expenses to be lower, resulting in an improved income forecast.

What’s next for the INDV share price

I reckon that the latest news will provide continued impetus for INDV’s share price. It’s now at 115p, up from the sub-100p levels it was at before the last week of December. The big decline started in late November, when it crashed 30% in a day following news that its former parent company — Reckitt Benckiser — had filed a £1bn claim on it.

Even now the share price is still much lower than its 131p levels at the time. But at least it’s now closer than ever to getting back there.

When I last wrote about Indivior, after its share price fall, my sense was that its share price would be dependent more on its own performance than anything else. If the share price reaction to its latest results is anything to go by, it only proves the point I was making at the time. If its performance remains consistent, I reckon that its share price can climb up further.

This is especially so in today’s bullish market, where investors are rewarding companies that are performing well.

Battling the opioid crisis

Moreover, the seriousness of the opioid crisis is big and rising, an issue that Indivior is well placed to address. According to the World Health Organisation, globally 0.5m deaths are caused by drug use every year, of which 70% are opioid-related. Moreover, between 2010 and 2018, the number of people dying of opioid overdose in the US increased by 120%.

Past problems still haunt

Despite this, as an investor I’m cautious because of INDV’s problems from the recent past, which include accusations of mis-selling and resulted in its former CEO being imprisoned. Almost two months after I wrote about INDV, it indeed appears to have put the episode behind it. It has also said that Reckitt Benckiser’s claim is without merit.

Further, its financials had suffered quite the blow in the first nine months of 2020, with a sharp decline in revenue. The latest numbers, then, are a surprise development and not one that reflects the inherent, ongoing strength of the company.

I think the INDV stock looks much better after its results than it did two months ago when it was far more in the thick of a crisis. It could continue to see improvements from here. But I really want to see some more predictability to its financials before buying the stock.

Manika Premsingh has no position in any of the shares mentioned. The Motley Fool UK has no position in any of the shares mentioned.

Indivior share price data is direct from the London Stock Exchange
Your Recent History
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

Log in to ADVFN
Register Now

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

Support: +44 (0) 203 8794 460 |

V: D: 20230607 03:36:47